Pharmaceuticals Company Seeking Loan in Aurangabad, India
We are pharma company working in Maharashtra state, launching soon in MP, Gujarat & Karnataka.
This transaction has concluded.
| Established | 10-20 year(s) |
| Employees | 10 - 50 |
| Legal Entity | Private Limited Company |
| Reported Sales | USD 220 thousand |
| Run Rate Sales | USD 110 thousand |
| EBITDA Margin | 10 % |
| Industries | Pharmaceuticals |
| Locations | Aurangabad |
| Local Time | 6:19 PM Asia / Kolkata |
| Listed By | Advisor / Business Broker |
| Status | Moderately Active |
Seeking Loan
USD
220 thousand
for
10.0%
annual interest,
5
years
(Native Currency: INR 20,000,000)
Reason: Expansion of our business.
Collateral Available: USD 220 thousand
Includes physical assets worth
USD
110 thousand
Interested to connect with advisors
Business Overview
We are pharmaceutical company operating in 25 + districts in Maharashtra launching soon in 24 districts as well as launching in MP & Gujarat.
Products & Services Overview
PARIFLOX 400 TAB.PANTOPAN TAB.
PANTOPAN D TAB.
PAREICOLD-5 TAB.
PARICEF 250.
PARICEF 500.
AZIPAR 250.
AZIPAR 500.
PARIDOME CAP.
Hbpar CAP.
PROVIT-FZ CAP.
Facilities Overview
Having office at aurangabad, Pune.
Capitalization Overview
Not Disclosed
Recent Activity
-
Earlier than 15 daysClient Acquisition Manager, Bengaluru, Financial Advisor connected with the Business
-
Earlier than 15 daysMarketing Head, Investment, Canada, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysHead International Business, Chemicals Business, Mumbai, Corporate Investor / Buyer connected with the Business
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
